Catalent Pharma Solutions & NewMarket Sign Development Agreement
Catalent Pharma Solutions and NewMarket Pharmaceuticals LLC recently announced they have entered into an agreement to jointly formulate and develop a portfolio of products for treating production and companion animals using Catalent’s proprietary, market-leading Zydis fast-dissolve technology and NewMarket’s DSI platform (Direct Systemic Introduction, patent pending).
NewMarket Pharmaceuticals is currently developing five drugs that will combine Catalent’s Zydis fast-dissolve and their own DSI technologies, initially including NSAIDs, beta agonists, proton pump inhibitors, and behavior modifiers across a variety of species, including horses, dogs, and cattle, with plans to expand the range in other classes. These new animal health products are expected to provide significant advantages over existing formulations currently used across a spectrum of indications for companion animals, equine, and production animals.
“These easy-to-use formulations could revolutionize the way we treat animals by providing for a simple, efficient, accurate method of treatment without the use of needles,” said Mark Ridall, CEO of NewMarket Pharmaceuticals.
“This partnership with NewMarket Pharmaceuticals demonstrates not only our commitment to provide more products and better treatments to our customers, but also signifies the versatile benefits that our Zydis fast-dissolve technology continues to deliver,” added Paul Jenkins, Global VP of Catalent’s ODT business.
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings, and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions.
NewMarket Pharmaceuticals was founded with the purpose of modernizing drug delivery systems for the treatment of animals. The company has identified a means by which established drugs that have proven safety and efficacy profiles, but exist in outdated or inefficient delivery systems, can be reformulated and administered to animals in a faster, safer, easier, and more accurate manner that has the potential to significantly expand the market for these drugs.
Total Page Views: 1228
